{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:04:28Z","timestamp":1780985068090,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14463-9","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:39:08Z","timestamp":1780724348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An international observational study on transition of care from paediatric to adult services for patients with mucopolysaccharidosis II"],"prefix":"10.1186","volume":"26","author":[{"given":"Karolina M.","family":"Stepien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olulade","family":"Ayodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Audi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia del","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"14463_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/1054-139X(93)90143-D","volume":"14","author":"RW Blum","year":"1993","unstructured":"Blum RW, Garell D, Hodgman CH, Jorissen TW, Okinow NA, Orr DP, et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 1993;14:570\u201376.","journal-title":"J Adolesc Health"},{"key":"14463_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","volume":"40","author":"BK Burton","year":"2017","unstructured":"Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2017;40:867\u201374.","journal-title":"J Inherit Metab Dis"},{"key":"14463_CR3","doi-asserted-by":"publisher","first-page":"7888","DOI":"10.3390\/ijms22157888","volume":"22","author":"CS Hampe","year":"2021","unstructured":"Hampe CS, Yund BD, Orchard PJ, Lund TC, Wesley J, McIvor RS. Differences in MPS I and MPS II disease manifestations. Int J Mol Sci. 2021;22:7888.","journal-title":"Int J Mol Sci"},{"key":"14463_CR4","first-page":"101005","volume":"37","author":"H Lau","year":"2023","unstructured":"Lau H, Harmatz P, Botha J, Audi J, Link B. Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: an analysis from the Hunter Outcome Survey. Mol Genet Metab Rep. 2023;37:101005.","journal-title":"Mol Genet Metab Rep"},{"key":"14463_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","volume":"33","author":"R Giugliani","year":"2010","unstructured":"Giugliani R, Federhen A, Rojas MV, Vieira T, Artigalas O, Pinto LL, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33:589\u2013604.","journal-title":"Genet Mol Biol"},{"key":"14463_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13023-020-01382-z","volume":"15","author":"KM Stepien","year":"2020","unstructured":"Stepien KM, Gevorkyan AK, Hendriksz CJ, Lobzhanidze TV, P\u00e9rez-L\u00f3pez J, Tol G, et al. Critical clinical situations in adult patients with mucopolysaccharidoses (MPS). Orphanet J Rare Dis. 2020;15:114.","journal-title":"Orphanet J Rare Dis"},{"key":"14463_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","volume":"5","author":"M Stapleton","year":"2017","unstructured":"Stapleton M, Kubaski F, Mason RW, Yabe H, Suzuki Y, Orii KE, et al. Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome). Expert Opin Orphan Drugs. 2017;5:295\u2013307.","journal-title":"Expert Opin Orphan Drugs"},{"key":"14463_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","volume":"34","author":"EA Braunlin","year":"2011","unstructured":"Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183\u201397.","journal-title":"J Inherit Metab Dis"},{"key":"14463_CR9","first-page":"100508","volume":"21","author":"C Lampe","year":"2019","unstructured":"Lampe C, McNelly B, Gevorkian AK, Hendriksz CJ, Lobzhanidze TV, Perez-Lopez J, et al. Transition of patients with mucopolysaccharidosis from paediatric to adult care. Mol Genet Metab Rep. 2019;21:100508.","journal-title":"Mol Genet Metab Rep"},{"key":"14463_CR10","first-page":"523","volume":"19","author":"KM St\u0119pie\u0144","year":"2015","unstructured":"St\u0119pie\u0144 KM, Hendriksz CJ. The principles of the transition process from paediatric to adult services in inborn errors of metabolism\u2014own experience. Dev Period Med. 2015;19:523\u201327.","journal-title":"Dev Period Med"},{"key":"14463_CR11","doi-asserted-by":"publisher","first-page":"1439236","DOI":"10.3389\/fped.2024.1439236","volume":"12","author":"KM Stepien","year":"2024","unstructured":"Stepien KM, \u017dnidar I, Kie\u0107-Wilk B, Jones A, Castillo-Garc\u00eda D, Abdelwahab M, et al. Transition of patients with Gaucher disease type 1 from pediatric to adult care: results from two international surveys of patients and health care professionals. Front Pediatr. 2024;12:1439236.","journal-title":"Front. Pediatr"},{"key":"14463_CR12","doi-asserted-by":"publisher","first-page":"652358","DOI":"10.3389\/fmed.2021.652358","volume":"8","author":"KM Stepien","year":"2021","unstructured":"Stepien KM, Kiec-Wilk B, Lampe C, Tangeraas T, Cefalo G, Belmatoug N, et al. Challenges in transition from childhood to adulthood care in rare metabolic diseases: results from the first multi-center European survey. Front Med (Lausanne). 2021;8:652358.","journal-title":"Front Med (Lausanne)"},{"key":"14463_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s13023-022-02593-2","volume":"17","author":"N Guffon","year":"2022","unstructured":"Guffon N, Genevaz D, Lacombe D, Le Peillet Feuillet E, Bausson P, Noel E, et al. Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study. Orphanet J Rare Dis. 2022;17:448.","journal-title":"Orphanet J Rare Dis"},{"key":"14463_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-6-72","volume":"6","author":"M Scarpa","year":"2011","unstructured":"Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72.","journal-title":"Orphanet J Rare Dis"},{"key":"14463_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II\u2013a historical review based on data from the Hunter Outcome survey (HOS). J Inherit Metab Dis. 2009;32:534\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"14463_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13023-016-0521-0","volume":"11","author":"S Somanadhan","year":"2016","unstructured":"Somanadhan S, Larkin PJ. Parents\u2019 experiences of living with, and caring for children, adolescents and young adults with mucopolysaccharidosis (MPS). Orphanet J Rare Dis. 2016;11:138.","journal-title":"Orphanet J Rare Dis"},{"key":"14463_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10897-013-9579-1","volume":"22","author":"R Freedman","year":"2013","unstructured":"Freedman R, Sahhar M, Curnow L, Lee J, Peters H. Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families. J Genetic Couns. 2013;22:517\u201332.","journal-title":"J Genetic Couns"},{"key":"14463_CR18","doi-asserted-by":"crossref","unstructured":"Zengin M, Yayan EH, Ak\u0131nc\u0131 A. Difficulties experienced by Turkish parents and their coping strategies: children with mucopolysaccharidosis. J Pediatr Nurs. 2020;53:e142\u201348.","DOI":"10.1016\/j.pedn.2020.03.009"},{"key":"14463_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.paed.2007.09.007","volume":"17","author":"JE McDonagh","year":"2007","unstructured":"McDonagh JE. Transition of care: How should we do it? Paediatr Child Health. 2007;17:480\u201384.","journal-title":"Paediatr Child Health"},{"key":"14463_CR20","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1093\/rheumatology\/keaa168","volume":"59","author":"A Kelly","year":"2020","unstructured":"Kelly A, Niddrie F, Tunnicliffe DJ, Matus Gonzalez A, Hanson C, Jiang I, et al. Patients\u2019 attitudes and experiences of transition from paediatric to adult healthcare in rheumatology: a qualitative systematic review. Rheumatol (Oxford). 2020;59:3737\u201350.","journal-title":"Rheumatol (Oxford)"},{"key":"14463_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pedn.2020.08.021","volume":"55","author":"M Varty","year":"2020","unstructured":"Varty M, Speller-Brown B, Phillips L, Kelly KP. Youths\u2019 experiences of transition from pediatric to adult care: an updated qualitative metasynthesis. J Pediatr Nurs. 2020;55:201\u201310.","journal-title":"J Pediatr Nurs"},{"key":"14463_CR22","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.gim.2022.04.018","volume":"24","author":"JI Gold","year":"2022","unstructured":"Gold JI, Gold NB, Strong A, Tully E, Xiao R, Schwartz LA, et al. The current state of adult metabolic medicine in the United States: results of a nationwide survey. Genet Med. 2022;24:1722\u201331.","journal-title":"Genet Med"},{"key":"14463_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12913-021-06567-1","volume":"21","author":"M Saarij\u00e4rvi","year":"2021","unstructured":"Saarij\u00e4rvi M, Wallin L, Moons P, Gyllensten H, Bratt EL. Mechanisms of impact and experiences of a person-centred transition programme for adolescents with CHD: the Stepstones project. BMC Health Serv Res. 2021;21:573.","journal-title":"BMC Health Serv Res"},{"key":"14463_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s12913-023-09644-9","volume":"23","author":"Y Zurynski","year":"2023","unstructured":"Zurynski Y, Carrigan A, Meulenbroeks I, Sarkies MN, Dammery G, Halim N, et al. Transition models of care for type 1 diabetes: a systematic review. BMC Health Serv Res. 2023;23:779.","journal-title":"BMC Health Serv Res"},{"key":"14463_CR25","doi-asserted-by":"publisher","first-page":"104891","DOI":"10.1016\/j.ejmg.2023.104891","volume":"67","author":"D Scognamiglio","year":"2024","unstructured":"Scognamiglio D, Boarini M, Forgia MC, Grippa E, Forni S, Sergi A, et al. Defining priorities in the transition from paediatric to adult healthcare for rare bone disease patients: a dialogic approach. Eur J Med Genet. 2024;67:104891.","journal-title":"Eur J Med Genet"},{"key":"14463_CR26","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.3390\/jcm11195805","volume":"11","author":"JI Gold","year":"2022","unstructured":"Gold JI, Stepien KM. Healthcare transition in inherited metabolic disorders\u2013Is a collaborative approach between US and European centers possible? J Clin Med. 2022;11:5805.","journal-title":"J Clin Med"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14463-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14463-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14463-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:49:01Z","timestamp":1780984141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14463-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14463"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14463-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practice published by the International Society for Pharmacoepidemiology and the laws and regulations of the countries in which the research was conducted. Ethical approval for the study was obtained from Salus Institutional Review Board in all countries except Canada. Ethical approval in Canada was obtained from Veritas. All participants were required to provide written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K. Stepien has received consulting fees and\/or participated in advisory boards for BioMarin Pharmaceutical, Chiesi, Sanofi Genzyme, Sigilon Therapeutics and Takeda. O. Ayodele is a full-time employee of Takeda Development Center Americas, Inc. and stockholder of Takeda Pharmaceutical Company Limited. J. Muenzer has received consulting fees and\/or participated in advisory boards for Denali Therapeutics, JCR Pharmaceuticals, REGENXBIO, Sanofi Genzyme and Takeda. He is a Principal Investigator for a post-trial access programme for intrathecal ERT for the neuronopathic form of MPS II (sponsored by Takeda), a phase 1\/2 gene editing trial for adults with MPS II (sponsored by Sangamo Therapeutics), and phase 1\/2 and phase 2\/3 trials of IV ERT for MPS II (sponsored by Denali Therapeutics). R. Giugliani has received consulting fees, fees for service, speaker fees and\/or travel expenses from and\/or has participated in advisory boards for Abeona Therapeutics, Alnylam Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical, Chiesi, Inventiva Pharma, Janssen Pharmaceuticals, JCR Pharmaceuticals, Novartis, Orphan Disease Center, Praxis Precision Medicines, PTC Therapeutics, REGENXBIO, Sanofi Genzyme, Sigilon Therapeutics, Swedish Orphan Biovitrum, Takeda and Ultragenyx. He has performed contracted research for or received research grants from Allievex, Amicus Therapeutics, BioMarin Pharmaceutical, GC Pharma, Idorsia Pharmaceuticals, Janssen Pharmaceuticals, JCR Pharmaceuticals, Lysogene, Sanofi Genzyme, Takeda and Ultragenyx. M. Scarpa has received consulting fees, fees for service and\/or participated in advisory boards for Actelion Pharmaceuticals, Alexion Pharmaceuticals, BioMarin Pharmaceuticals, Chiesi, Orchard Therapeutics, Orphazyme, Paradigm Biopharmaceuticals, PTC Therapeutics, Sanofi Genzyme, Takeda and Ultragenyx. He has performed contracted research for Alexion Pharmaceuticals, BioMarin Pharmaceutical, CTD, Orchard Therapeutics, Orphazyme, Paradigm Biopharmaceuticals, PTC Therapeutics, Sanofi Genzyme and Takeda. C. Lampe has received advisory board and speaker fees, travel expenses and consultancy fees from Alexion Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical, Chiesi, REGENXBIO, Sanofi and Takeda. J. Audi was an employee of Takeda Pharmaceuticals International AG and a stockholder of Takeda Pharmaceuticals Company Limited at the time of this analysis (current affiliation is Ultragenyx Europe GmbH, Basel, Switzerland). S. Jain is a full-time employee of Takeda Development Center Americas Inc. and a stockholder of Takeda Pharmaceutical Company Limited. C. Jackson was an employee of Sprout Health Solutions, which provides research and other consulting services to multiple pharmaceutical and biotechnology companies, at the time the study was performed. Sprout Health Solutions was contracted by Takeda Pharmaceutical Company Limited to perform this study. L. Meade is an employee of Sprout Health Solutions, which provides research and other consulting services to multiple pharmaceutical and biotech companies. Sprout Health Solutions was contracted by Takeda Pharmaceutical Company Limited to perform this study. M. del Toro has received consulting fees and speaker honoraria, travel expenses and congress fees from BioMarin, Orchard, Sanofi Genzyme and Takeda, and is an investigator for industrial trials (Takeda, Ultragenyx, Denali, Chiesi).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"808"}}